CCTA 3.0 | Remove the Blindfold: Integrating Plaque Biology & Physiology for Clinical Decisions

Novel Technologies at SCCT 2026: Kelly Huang on Elucid's Plaque-IQ and BioIntegrated FFR-CT*

Webinar | CCTA 3.0: From Plaque Analysis to FFR-CT and a comprehensive clinical platform

From Voxels to Prescriptions and Beyond: Webinar 11-24-2025, Hosted by SCCT

Webinar | CT Virtual Histology: Real-World Solutions for CT Plaque Analysis

CT Virtual Histology: Solutions for CT-Derived Plaque Analysis | with Cardiac Wire at SCCT 2025

Diagnostic Imaging: Emerging Concepts in CT-Guided Treatment of Coronary Artery Disease

Elucid Introduction

Elucid at SCCT 2024: Precision Cardiovascular Pathways with Histology-based Plaque Quantitation

Webinar: Optimizing Coronary CTA: Reimbursement, Reporting and Plaque (SCCT)

Webinar: Optimizing Coronary CTA - A Focus on Quality Imaging and Access to Care (SCCT)

Todd Villines, MD: The Evolving Role of Advanced Plaque Analysis In Preventive Care

Todd C. Villines, MD: Will CTCA Compete with or Improve the Use of Intravascular Imaging?

Todd C. Villines, MD: Advanced Plaque Analysis in Clinical Practice - Is there a role?

Webinar: Dr. Sarah Rinehart and Dr. Todd Villines on the newest plaque analysis technology using CT

Elucid's Company Culture

Webinar: Dr. Maros Ferencik and Dr. Todd Villines on the newest plaque analysis technology using CT

Dr. Todd C. Villines presents at the 2022 Vulnerable Plaque and Patient Meeting in Galway.

The Importance of Tailoring Cardiovascular Disease Therapies - Andrew Buckler, CTO of Elucid

Tomorrow's Technology - Renu Virmani, MD

Postcard Study Results - Matthew Budoff, MD

Elucid Webcast

A Tremendous Differentiator - Robert Pelberg, MD, Christ Hospital

FDA Cleared Non-Invasive Tool - Elucid

At The Heart Of What The Value Is - Leslee Shaw, MD, PhD, Mount Sinai

Game Changing Plaque Characterization Platform - Robert Pelberg, MD, Christ Hospital

Using Histology to personalize Patient Care - Blake Richards, CEO of Elucid

Detecting at the Earliest Stages of Heart Disease - Elucid

Hitting the Mark - Robert Pelberg, MD, Christ Hospital

Make Tailored and More Precise Treatment Decisions - Elucid

Advancing Diagnostic Evaluation - Elucid

The Management of Cardiovascular Disease - Andrew Buckler, Founder and CTO of Elucid

Ability to Plan for Procedures - Blake Richards, CEO of Elucid

Putting More Control into Physician's Hands - Blake Richards, CEO of Elucid

Software Integration Opportunities - Blake Richards, CEO of Elucid

Integrating Imaging Technology with Biology - Andrew Buckler, CTO of Elucid

How Elucid Differentiates Itself - Blake Richards, CEO of Elucid

Access, Value and Outcomes - Jason Bottiglieri, CCO of Elucid

What Data Science Can Teach Us - Andrew Buckler, Founder, President, and CTO of Elucid

FFRCT Solution Based on the Morphology in the Vessel Wall - Jason Bottiglieri, Elucid’s CCO

The Unique Combination of Radiology & Biology - Blake Richards, CEO of Elucid

Tech Grounded in Histopathology - Blake Richards, CEO of Elucid

The Philosophy & Discipline of Elucid Technology- Andrew Buckler, Founder, President & CTO of Elucid

Identifying Plaque Composition - Blake Richards, CEO of Elucid

Going Beyond What The Human Eye Can Do - Blake Richards, CEO of Elucid

Personalization in Cardiac Care - Andrew Buckler, President and CTO of Elucid Bio

Understanding the Lumen - Jason Bottiglieri, CCO of Elucid

Tipping the Scales - Jason Bottiglieri, CCO of Elucid Bio

The Convergence of Technology - Andrew Buckler, CTO of Elucid Bio

Improving Assessments and Clarifying the Best Treatment - Blake Richards, CEO of Elucid